Continuing Education

October 17, 2022


The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

ACCMEThe Endocrine Society designates this activity for a maximum of 110.0 AMA PRA Category 1 Credits for premium registrants and up to 27.25 for standard registrants*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 27.25 Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

*110 AMA PRA Category 1 credits are exclusive to premium registrants. Standard registrants are eligible for up to 27.25 AMA PRA Category 1 credits.

European Accreditation Council for Continuing Medical Education

The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby: European physicians attending an event in the USA had their credits recognized in Europe and American physicians attending an event in Europe had their credits recognized in the USA.

The Endocrine Society designates this educational activity for a maximum of 110 AMA PRA Category 1 Credit(s)™ for premium registrants and 27.25 AMA PRA Category 1 Credit(s) for standard registrants. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

Royal College of Physicians and Surgeons of Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program. Instructions regarding this conversion can be found here.


August 18, 2023: Standard registration credit claim expiration
December 31, 2023: Premium registration credit claim expiration


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following AMSC members reported relevant financial relationships:

Irina Bancos, MD, Advisory Board: Adrenas, HRA Pharma, Corcept, Recordati, Consulting: HRA Pharma, Corcept, Sparrow Pharmaceutics, Recordati, Writer: Elsevier, Funding for Investigator Initiated Award: Recordati, NIH, Reviewer: Dynamed 

Andrew Bauer, MD, Speaker: Hexal, AG 

Denise D. Belsham, PhD, President: Pan American Neuroendocrine Society 

Kristien Boelaert, MD, PhD, Advisory Board: Pfizer, EISAI; Member and Awards Committee: American Thyroid Association; Member, Council Member, Clinical Committee Chair Elect: Society for Endocrinology; Member: British Thyroid Association, European Thyroid Association, European Endocrine Society, British Thyroid Association 

Massimiliano Caprio, MD, PhD, Grant Recipient: Bayer AG; Associate Editor: Frontiers in Endocrinology 

Barbara Gisella Carranza Leon, MD, Co-investigator: Novartis, IONIS Phamaceutical Inc, NIH, FH Foundation, Regenxbio, Inc.; Member of the Maintenance of Certification Committee: American Board of Obesity Medicine 

Bart L. Clarke, MD, Advisory Board: Bristol-Myers Squibb; Consulting Fee: Shire/Takeda, Inc., Calcilytix, Inc., Amolyt, Inc., Entera Bio, Extend Bio, ShouTi Pharma; Site Principal Investigator: Shire/Takeda, Inc., Ascendis, Inc., Chugai, Inc. 

Carolyn L. Cummins, PhD, Member: American Association of Pharmaceutical Scientists, Canadian Society of Pharmaceutical Sciences; Reviewer and Grantee: Canadian Institutes of Health Research 

Aime T. Franco, PhD, Advisory Board: American Thyroid Association  

Daniel E. Frigo, PhD, Consultant and Grant Recipient: GTx, Inc. 

Adda Grimberg, MD, Advisory Board: Pfizer, Consultant: Pediatric Endocrine Society Growth Hormone Deficiency Knowledge Center, Sponsored by Sandoz; Grant Recipient: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Advisory Board: Pediatric Endocrine Society, Growth Hormone Research Society, Editorial Board: Pediatric Endocrinology Reviews; Speaker: Midwest Pediatric Endocrine Society, Canadian Pediatric Endocrine Group 

Ole-Petter Hamnvik, MBBChBAO, MMSc, MRCPI, Education Editor: New England Journal of Medicine 

Shingo Kajimura, PhD, Editorial Activities: Molecular Metabolism, Molecular and Cellular Biology, Journal of Clinical Investigation Insight, Life Science Alliance, Reviewer: NIDDK, Research Support: Daiichi Sankyo Inc., Ltd, Calico Life Sciences LLC.  

Marta Korbonits, MD, PhD, Speaker: Pfizer, Ipsen; Associate Editor: JES, Endocrine Society; Scientific Advisor: ONO, NorvoNordisk, Corcept; Investigator: Crinetics 

Monica M. Laronda, PhD, Advisory Board Member: Dimension Inx; Section Editor: Reproductive Biomedicine Online (RBMO) 

Ellis R. Levin, MD, Stock Owner: Gilead Inc., Amgen 

Christopher McCartney, MD, Grant Recipient: NIH, Reviewer: NIH 

Raghavendra Mirmira, PhD, MD, Editor: Journal of Clinical Endocrinology and Metabolism, Advisory Board: Veralox Therapeutics, Investigator-Initiated Award: Veralox Therapeutics, HiberCell, Inc. 

Erik Russell Nelson, BSc, PhD, Member: American Physiological Society, American Association for Cancer Research, American Association for the Advancement of Science 

Gabrielle Page-Wilson, MD, Advisory Board: Strongbridge Biopharma, Recordati Rare Diseases, Inc., Xeris BioPharma; Consultant: Xeris BioPharma 

Yumie Rhee, MD, PhD, Ambassador: American Society of Bone and Mineral Research, Committee: Korean Endocrine Society, Korean Society of Bone and Mineral Research 

Stephen Rosenthal, MD, Board of Directors and Member: World Professional Association for Transgender Health 

Jenny A. Visser, PhD, Member: Dutch Endocrine Society (NVE), European Endocrine Society (ESE), Women in Endocrinology (WE), Organisation for the Study of Sex Differences (OSSD), Advisory Board: European Endocrine Society (ESE), Editorial Board: Frontiers in Endocrinology, Metabolism, Associate Editor: Human Reproduction Update 

W. Edward Visser, MD, PhD, Royalties (Institution): Egetis Therapeutics 

Bu Beng Yeap, MBBS, FRACP, PhD, Advisory Board: NovoNordisk, Bayer, Advisor: Lawley Pharmaceuticals, Speaker: AstraZeneca, Besins, Philippine Society for Endocrinology, Diabetes and Metabolism, View Street Medical, President: Endocrine Society of Australia, Associate Editor: Asian Journal of Andrology, Journal of Gerontology Medical Sciences, Editorial Board: Journal of Gerontology Medical Sciences, Journal of Clinical Endocrinology and Metabolism, Maturitas 

Elaine Wei-Yin Yu, MD, Grant Recipient: Amgen, Stock Owner: Opko 

Maria-Christina  Zennaro, MD, PhD, Member: Societé Française d'Endocrinology, Societé Française de Caridologie, European Network for the Study of Adrenal Tumors; Executive Committee: International Aldosterone Conference; President: European Section of Aldosterone Council (ESAC)-France; French network on adrenal tumors COMETE 

The following AMSC members reported no relevant financial relationships: 

Ana Paula Abreu, MD, PhD; Benson Akingbemi, PhD, DVM; Ernesto Bernal-Mizrachi, MD; Davide Calebiro, MD; Jaydira Del Rivero, MD; T. Raj Kumar, PhD, MPHIL, MSC; Claire Newton, BSc, PhD; Matti Poutanen, PhD; Kimia Saleh Anaraki, MD; and Marc J. Tetel, PhD

Disclosure information for presenters is included in their individual recorded presentations.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.



The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.